Related Experiment Video
Updated: Sep 22, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
A Case of Membranous Nephropathy Hypothesized to be Associated With COVID-19 Vaccine
Wahida Rashid1, Heba Mousa1, Jahanzeb Khan1
1Internal Medicine, Baptist Health - University of Arkansas for Medical Sciences, North Little Rock, USA.
Insights
A patient developed severe kidney disease, including membranous nephropathy, after a COVID-19 infection and initial vaccine dose. His kidney function recovered after treatment, but further study is needed on COVID-19 vaccination and kidney injury risks.
Area of Science:
- Nephrology
- Immunology
- Vaccinology
Background:
- Essential hypertension is a common comorbidity.
- Coronavirus disease 2019 (COVID-19) infection can lead to various complications.
- COVID-19 vaccines have been developed to prevent severe disease.
Observation:
- A 56-year-old male presented with acute kidney injury (creatinine 13 mg/dL) six months after a suspected COVID-19-like illness.
- He developed worsening dyspnea and edema after his first Moderna COVID-19 vaccine dose.
- Urinalysis revealed nephrotic-range proteinuria and eosinophils; serum PLA2R antibodies were positive.
Findings:
- Renal biopsy confirmed membranous glomerulonephritis (MN) with acute interstitial nephritis.
- Positive PLA2R staining indicated primary MN.
- The patient's renal function normalized after treatment with prednisone, rituximab, and temporary hemodialysis.
Implications:
- This case suggests a potential association between COVID-19 vaccination and the onset of membranous nephropathy.
- Further research is required to establish a causal link and understand the mechanisms of vaccine-induced kidney injury.
- Identifying predisposing factors in vaccinated individuals is crucial for risk assessment and prevention strategies.
Abstract:
A 56-year-old male patient with a medical history of essential hypertension was referred to the emergency room after he was found to have a serum creatinine level of 13 mg/dL at his primary care physician's office. The patient reported that he had developed a coronavirus disease 2019 (COVID-19)-like infection six months prior that was not confirmed. Two months later, he started to notice dyspnea on exertion and bilateral lower limb swelling and was started on furosemide. He received the first dose of the Moderna COVID-19 vaccine a month before the presentation but did not receive the second dose. Subsequently, his lower limb swelling and exertional dyspnea started worsening. He denied any new medication, dysuria, oliguria, hematuria, fever, or any other symptoms. Initial evaluation was consistent with kidney failure. Hypocalcemia and hyperphosphatemia were noted, along with medical renal disease on renal ultrasound. Eosinophils and nephrotic-range proteinuria were found in the urine. His serum phospholipase A2 receptor (PLA2R) antibodies were positive. A renal biopsy showed membranous glomerulonephritis with moderate segmental sclerosis, as well as tubulointerstitial fibrosis with neutrophils, consistent with acute interstitial nephritis. Positive staining for PLA2R in the glomerular deposits suggested primary membranous nephropathy (MN). He was treated with prednisone first, and when the kidney biopsy was conclusive for membranous glomerulopathy, he was started on rituximab. On admission, he received hemodialysis intermittently, but this was stopped a month after discharge as his renal function normalized. Recently, there have been numerous cases reported with new onset of glomerular disease after receiving the COVID-19 vaccine. Further studies of vaccinated patients are needed to determine whether the severe acute respiratory syndrome coronavirus 2 virus vaccination is associated with a higher risk of MN and to identify potential predisposing factors and mechanisms of kidney injury in patients in whom it occurs.
More Related Videos
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Related Concept Videos
Nephrotic Syndrome I : Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury III: Clinical Manifestations
Cross-reactivity